Pathophysiology and Risk Factors of NSAID-Induced Gastrointestinal Bleeding

Mechanism of Injury and Clinical Manifestations

NSAIDs cause gastrointestinal bleeding through two distinct mechanisms: systemic inhibition of gastroprotective prostaglandin synthesis and direct topical mucosal injury from the acidic drug molecules, as noted by the American Gastroenterological Association 1, 2, 3
The American College of Gastroenterology recommends considering the risk of gastrointestinal bleeding when prescribing NSAIDs, as the majority of NSAID-induced ulcers are asymptomatic 1, 2
NSAID use increases the average relative risk of serious GI complications 3- to 5-fold compared to nonusers, according to the American Gastroenterological Association 1, 2

History of previous peptic ulcer or prior NSAID-related GI complication represents the single most significant risk factor, increasing the likelihood of a GI event by 2.5- to 13.5-fold, as reported by the American College of Gastroenterology 1, 2, 4
Advanced age increases the risk of GI events, with patients over 65 years having a 2- to 3.5-fold increased risk, as noted by the American Geriatrics Society 1, 2, 4
Concomitant corticosteroid use increases the risk of GI events by approximately 2-fold, according to the American College of Rheumatology 1, 4, 5
Concomitant anticoagulant use increases the risk of GI bleeding by approximately 3-fold, as reported by the American Heart Association 3, 4

All NSAID classes demonstrate a linear dose-response relationship to adverse GI events, as noted by the American Gastroenterological Association 1, 2, 6
High-dose NSAID use or combinations of NSAIDs substantially increase the risk of GI events, according to the American College of Gastroenterology 1, 2
When aspirin is combined with NSAIDs, the relative risk of GI bleeding increases to more than 10-fold compared to either agent alone, as reported by the American Heart Association 1, 2, 6

Lower GI tract complications may account for 20% of total NSAID-associated GI morbidity, though the exact incidence remains poorly defined, as noted by the American Gastroenterological Association 1, 2
NSAIDs can cause ulcers, strictures, and diaphragms throughout the small intestine and colon, according to the American College of Gastroenterology 6
Dyspepsia and GI discomfort do not correlate well with clinically significant ulcerations, and symptomatic relief does not indicate mucosal healing or reduced bleeding risk, as reported by the American Family Physician 3

Upper gastrointestinal bleeding occurs in 1 of every 20 NSAID users overall, and in 1 of 7 older adults using NSAIDs, according to the American College of Cardiology 7
The annual incidence of serious upper GI complications ranges from 0.2% to 1.9%, while the annual rate of all upper GI clinical events is 2.5% to 4.5%, as reported by the American College of Cardiology 7, 8
NSAID use accounts for approximately 107,000 hospitalizations and 16,500 deaths per year in the United States among patients with arthritis, as stated by the American College of Cardiology 7

Concomitant use of aspirin with any NSAID increases GI bleeding risk more than 10-fold, with annual risk reaching 5.6% for NSAID plus aspirin, according to the American College of Cardiology 7, 8
Age ≥65 years increases risk 2- to 3.5-fold, with elderly patients constituting 87.1% of high-risk NSAID users, as reported by the American College of Cardiology 7
Duration of NSAID therapy correlates with increased bleeding risk, though even short-term therapy carries significant risk, as stated by the American College of Cardiology 7

COX-2 selective inhibitors do not eliminate GI bleeding risk, particularly when combined with aspirin, which negates most of their gastroprotective advantage, as reported by the American College of Cardiology and the American Geriatrics Society 7, 8, 9

Adding any oral anticoagulant (including sulodexide) to NSAID therapy raises the risk of gastrointestinal (GI) bleeding by roughly three‑fold compared with NSAID use alone, and the overall risk can be 3–6 times the baseline population risk. 10

Active peptic ulcer disease or recent GI bleeding increases the combined bleeding risk by approximately 2.5–4‑fold. 11
Age > 65 years is associated with a 2–3.5‑fold higher risk of GI bleeding when NSAIDs are used with anticoagulants. 10

Clinicians should monitor for overt signs of GI bleeding (e.g., melena, hematemesis, unexplained anemia) in patients receiving both sulodexide and NSAIDs. 10
Blood pressure should be measured before initiating NSAIDs and monitored regularly, as NSAID therapy raises systolic pressure by an average of about 5 mm Hg. 10
Renal function monitoring is recommended because NSAIDs can impair renal perfusion through prostaglandin inhibition, especially when combined with sulodexide. 10
Caution is advised when NSAIDs are co‑prescribed with renin‑angiotensin system blockers (e.g., ACE inhibitors) or beta‑blockers, due to additive renal risk. 10
Avoid NSAIDs in patients with congestive heart failure, given the potential for sodium and fluid retention that can worsen cardiac status. 10

COX‑2 selective inhibitors (e.g., celecoxib) may be considered as an alternative to non‑selective NSAIDs for patients at moderate risk, although they do not completely eliminate GI bleeding risk. [11][12]